Sandoz Is Satisfied With US Pegfilgrastim Start
Promising Initial Signs For Ziextenzo
Executive Summary
Initial market signals from Sandoz’ US launch of its Ziextenzo pegfilgrastim biosimilar are promising, global Biopharmaceuticals head Pierre Bourdage told Generics Bulletin.
You may also be interested in...
Biocon And Mylan Prime Pegfilgrastim Expansion
Biocon-Mylan’s sBLA for pegfilgrastim made at a new Indian site gets an FDA go-ahead, facilitating a "multi-fold" scale up in capacity. But it will be interesting to watch how impactful this could be on market dynamics in the US, where more competition has arrived.
Biocon-Mylan Prime Pegfilgrastim Market Expansion
Biocon-Mylan’s sBLA approval for pegfilgrastim made at a new Indian site gets FDA go-ahead, facilitating a "multi-fold" scale up in capacity. But it will be interesting to watch how impactful this could be on market dynamics in the US, where more competition has arrived.
Sandoz Gets Approval For US Pegfilgrastim
Sandoz has finally received a much-awaited FDA approval for its pegfilgrastim biosimilar, Ziextenzo, which will be launched in the US “as soon as possible this year.”
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests:
